The hepatitis B virus (HBV), discovered in 1966, infects more than 350 million people
worldwide. 1 Hepatitis B is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease has improved. Several new and effective antiviral agents …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …

One third of the global population has been acutely infected with hepatitis B virus (HBV);
less than 1% of patients with acute infection will develop fulminant hepatitis. 1 Approximately …

Patients undergoing liver transplantation for hepatitis B–related liver disease are prone to
recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B …

Three–hundred and twenty–four patients were enrolled in an open–label, multicenter,
international study in which pre–and post–liver transplantation (LT) patients with recurrent …

Seventy–seven liver transplant candidates were enrolled in a multicenter study in which
patients were treated with lamivudine (100 mg daily) without the adjunctive use of hepatitis B …

Abstract Treatment of hepatitis B virus (HBV) with lamivudine is effective in suppressing virus
replication and results in reduced inflammatory activity. However, the emergence of …

BMS-200475 is a novel carbocyclic 2'-deoxyguanosine analog found to possess potent and
selective anti-hepatitis B virus (anti-HBV) activity. BMS-200475 is distinguished from …